EFFICACY AND SAFETY OF LENVATINIB COMBINED WITH DIFFERENT ANTI-PD-1 ANTIBODY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: A REAL WORLD EVIDENCE BASED RETROSPECTIVE STUDY

被引：0
|
作者：
Chen, Bowen [1 ]
Zhang, Linzhi [2 ,3 ]
Cheng, Jiamin, Sr. [2 ]
Yan, Tao [2 ]
Lu, Yinying [1 ]
机构：
[1] Peking Univ, Clin Med Sch 302, Beijing, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
来源：
HEPATOLOGY | 2021年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1045
引用
收藏
页码：637A / 638A
页数：2
相关论文
共 50 条
  • [31] Efficacy of Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective, Multicenter Study
    Ou, Xiangye
    Wu, Junyi
    Wu, Jiayi
    Fu, Yangkai
    Zeng, Zhenxin
    Li, Shuqun
    Li, Yinan
    Liu, Deyi
    Li, Han
    Li, Bin
    Zhou, Jianyin
    Zhuang, Shaowu
    Cheng, Shuqun
    Zhang, Zhibo
    Wang, Kai
    Qu, Shuang
    Yan, Maolin
    CANCER RESEARCH AND TREATMENT, 2024, 56 (04): : 1207 - 1218
  • [32] REAL WORLD EVIDENCE OF LENVATINIB IN ADVANCED HEPATOCELLULAR CARCINOMA: A MULTICENTER COHORT STUDY
    Nakano, Masahito
    Kuromatsu, Ryoko
    Niizeki, Takashi
    Okamura, Shusuke
    Iwamoto, Hideki
    Shimose, Shigeo
    Shirono, Tomotake
    Noda, Yu
    Kamachi, Naoki
    Koga, Hironori
    Torimura, Takuji
    HEPATOLOGY, 2019, 70 : 243A - 244A
  • [33] Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study
    Yang, Hui
    Yang, Tiequan
    Qiu, Guangpin
    Liu, Jie
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 1435 - 1443
  • [34] Comparative efficacy of PD-1 inhibitors plus lenvatinib and regorafenib after lenvatinib failure for advanced hepatocellular carcinoma: a real-world study
    Renguo Guan
    Jie Mei
    Shaohua Li
    Wenping Lin
    Min Deng
    Wei Wei
    Rongping Guo
    Hepatology International, 2023, 17 : 765 - 769
  • [35] Comparative efficacy of PD-1 inhibitors plus lenvatinib and regorafenib after lenvatinib failure for advanced hepatocellular carcinoma: a real-world study
    Guan, Renguo
    Mei, Jie
    Li, Shaohua
    Lin, Wenping
    Deng, Min
    Wei, Wei
    Guo, Rongping
    HEPATOLOGY INTERNATIONAL, 2023, 17 (03) : 765 - 769
  • [36] Tumor radiomic features on pretreatment MRI to predict response to lenvatinib plus an anti-PD-1 antibody in advanced hepatocellular carcinoma: a multicenter study
    Xu, Bin
    Dong, Sanyuan
    Bai, Xue-Li
    Song, Tian-Qiang
    Zhang, Bo-Heng
    Zhou, Le-Du
    Chen, Yong-Jun
    Zeng, Zhi-Ming
    Wang, Kui
    Zhao, Hai-Tao
    Lu, Na
    Zhang, Wei
    Li, Xu-Bin
    Zheng, Su-Su
    Long, Guo
    Yang, Yu-Chen
    Huang, Hua-Sheng
    Huang, Lan-Qing
    Wang, Yun-Chao
    Liang, Fei
    Zhu, Xiao-Dong
    Huang, Cheng
    Shen, Ying-Hao
    Zhou, Jian
    Zeng, Meng-Su
    Fan, Jia
    Rao, Sheng-Xiang
    Sun, Hui-Chuan
    LIVER CANCER, 2023, 12 (03) : 262 - 276
  • [37] Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
    O'Neil, Bert H.
    Wallmark, John M.
    Lorente, David
    Elez, Elena
    Raimbourg, Judith
    Gomez-Roca, Carlos
    Ejadi, Samuel
    Piha-Paul, Sarina A.
    Stein, Mark N.
    Razak, Albiruni R. Abdul
    Dotti, Katia
    Santoro, Armando
    Cohen, Roger B.
    Gould, Marlena
    Saraf, Sanatan
    Stein, Karen
    Han, Sae-Won
    PLOS ONE, 2017, 12 (12):
  • [38] MRI-based Nomogram Predicts the Risk of Progression of Unresectable Hepatocellular Carcinoma After Combined Lenvatinib and anti-PD-1 Antibody Therapy
    Sheng, Ruofan
    Zeng, Mengsu
    Jin, Kaipu
    Zhang, Yunfei
    Wu, Dong
    Sun, Huichuan
    ACADEMIC RADIOLOGY, 2022, 29 (06) : 819 - 829
  • [39] Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model
    Xue-Feng Liu
    Xiao-Dong Zhu
    Long-Hai Feng
    Xiao-Long Li
    Bin Xu
    Kang-Shuai Li
    Nan Xiao
    Ming Lei
    Hui-Chuan Sun
    Zhao-You Tang
    Experimental Hematology & Oncology, 11
  • [40] Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model
    Liu, Xue-Feng
    Zhu, Xiao-Dong
    Feng, Long-Hai
    Li, Xiao-Long
    Xu, Bin
    Li, Kang-Shuai
    Xiao, Nan
    Lei, Ming
    Sun, Hui-Chuan
    Tang, Zhao-You
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
12345